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Background. The outcome in patients with severe mitral regurgitation (MR) and impaired
ejection fraction (EF) is poorly described in the developing world where rheumatic heart
disease is endemic.
Objective. This  study  describes  the  effects  of  mitral  valve  replacement  (MVR)  on  left
ventricular (LV) function in patients with rheumatic MR. 
Methods. This  is  a  retrospective  analysis  of  all  subjects  with  severe  rheumatic  MR
undergoing  MVR  over  a  9  year  period  (2005-2013).  Clinical  and  echocardiographic
parameters were recorded pre-operatively, at 2 weeks, 6 weeks to 3 months and 6 months to
2 years following MVR.
Results. Of 132 patients included in the study, 66% (n=87) were NYHA class III-IV, 38%
(n=50) presented with clinical features of heart failure and 14% (n=19) had atrial fibrillation
prior  to  MVR.  The  echocardiogram  showed  increased  end  systolic  diameter  (ESD,
39.9±7.2mm), left atrial size (LA, 61.2±12.6mm), and pulmonary artery systolic pressures
(PASP,  59.5mmHg,  IQR  45-80mmHg).  Pre-operatively,  28%  (n=37)  of  subjects  had
impaired LV function (EF <60%). At 6 months to 2 years following MVR (n=93), 1% of
subjects were NYHA III-IV, 1% were in heart failure, and 7.6% had atrial fibrillation. Paired
analysis of 83 patients with complete datasets revealed that the EF was >55% in 87% (n=72)
pre-operatively, the number of patients with EF >55% dropped to 20% (n=17) at 2 weeks
postoperatively (p<0.001, 95% CI 0.02-0.09) and thereafter an EF > 55% was recorded in
60% (n=53) at the 6 months to 2 year follow up (p<0.001, 95% CI 0.1-0.5). After feeding all
clinical and echocardiographic variables into a predictive model only the ESD emerged as a
significant  predictor  of  postoperative  LV  dysfunction  (EF<  50%)  both  on  uni-  and
multivariate analysis. 
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Conclusion. Most subjects with severe rheumatic MR who  were subjected to surgery  had
advanced  disease  with  heart  failure,  indicating  that  preoperatively,  impairment  of LV
function  was  a  frequent  finding.  The  preoperative  ESD  was  the  only  predictor  of
postoperative LV dysfunction. This study calls for careful clinical assessment with regular
imaging and early referral for surgery in subjects with severe MR according to established




Rheumatic  heart  disease  (RHD)  is  a  recognized  sequelae  of  acute  rheumatic  fever  with
carditis in the younger population under the age of 25, following an autoimmune response to
streptococcal throat infection. It is prevalent in developing countries in Africa, the Middle
East, Central and South Asia, the South Pacific, and in poverty-stricken areas of developed
countries.[1]  The report  from the Global,  Regional,  and National  Burden of RHD, 1990-
2015, estimated that the age-standardized prevalence of rheumatic heart disease in 2015 was
444 cases per  100,000 population in countries  where RHD is endemic and 3.4 cases per
100,000 population for countries with a nonendemic pattern.[2] This has been attributed to
the  ongoing socio-economic  challenges  in the  developing  world,  with  overcrowding  and
poverty being major contributors. [2] 
In  South  Africa,  the  incidence  of  symptomatic  RHD was  reported  as  24.7  per  100,000
population in the city of Soweto over the past two decades. A much higher prevalence (20.2
cases  per  1000)  of  RHD  detected  by  echocardiography  was  reported  in  asymptomatic
children in Cape Town.[3] In contrast,  Cilliers et al recently demonstrated a decline in the
number of paediatric cases of ARF and RHD, from 64 cases in 1993 to only 3 cases in 2010,
at Chris Hani Baragwanath Academic Hospital in Soweto, South Africa. This was attributed
to improved socioeconomic conditions  and better  access to  health  care.  [4]  There are no
published data on RHD from KwaZulu-Natal.
Mitral regurgitation is the predominant valvular lesion in RHD.[5]  A systematic review and
meta-analysis of 33 articles reported that the mean age of presentation with RHD was 11
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years old; 53% of the populations analyzed were of male gender; 65% presented with mitral
regurgitation,  21%  had  aortic  regurgitation  and  15%  had  mitral  stenosis.[6]  Mitral
regurgitation results from disruption of any part of the mitral valve apparatus[7] 
The mitral valve apparatus is made up of the annulus, the anterior and posterior leaflets, and
the  chordae,  which  attach  the  leaflets  to  their  respective  papillary  muscles.  A  normally
functioning valve allows blood to flow unimpeded from the left atrium to the left ventricle
during diastole and prevents regurgitation during systole.  Normal mitral  valve function is
dependent not only on the integrity of the underlying valvular structure, but on that of the
adjacent myocardium as well. Mitral regurgitation is characterized as primary or secondary
MR,  the  former  denoting  lesions  of  the  valve  apparatus  itself  and  includes  degenerative
disease,  rheumatic  fever  with carditis,  rheumatic  heart  disease,  infective  endocarditis  and
papillary muscle rupture.[7,8] Secondary MR refers to regurgitation that occurs as a result of
dilatation  of  the  mitral  annular  ring  and  left  ventricular  myopathic  processes.[8]  The
mechanism of mitral regurgitation in rheumatic carditis involves annular dilatation, chordal
elongation and anterior mitral leaflet prolapse.[9,10]
As the lesions of MR progress, left  ventricular  volume overload ensues as a result  of an
increased regurgitant orifice area.[11] The volume loaded left ventricle increases LV diastolic
wall  stress  which  leads  to  the  development  of  further  LV chamber  enlargement.  During
systole the LV decompresses into the compliant low pressure left atrium while at the same
time ejecting into the systemic circulation, resulting in a falsely elevated ejection fraction.
[7,47] For this reason, though very simply estimated, the ejection fraction is a rather crude
indicator of contractile function in mitral regurgitation. Ahmed et al conducted a study of
severe degenerative MR in 27 subjects who were largely asymptomatic and had a mean pre-
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operative EF above 60%. Immunohistochemical stains of myocardial biopsies and magnetic
resonance imaging (MRI) of the heart were performed prior to and at six months following
surgery.  Oxidative  damage  as  evidenced  by  xanthine  oxidase  staining  and  lipofuscin
accumulation was evident, and MRI showed myofibrillar degeneration, the latter two being
markers of heart failure.[12] Interestingly, Ahmed’s patients selected for MVR had preserved
pre-operative left ventricular EF which showed a significant reduction at the 6 month follow
up,  suggesting  that  the  post-operative  EF  is  the  true  indicator  of  the  pathophysiologic
processes of chronic MR.[12] 
With the advent of echocardiography, more cases of RHD can be detected, and analysis of
the  valve  structure  and  left  ventricular  dimensions  performed.[13]  Transthoracic
echocardiography  is  a  sensitive  diagnostic  tool  that  has  been  able  to  detect  cases  of
subclinical and clinical RHD as compared to clinical examination alone.[14,15] Diagnostic
echocardiographic criteria were proposed in 2012 by the World Heart Federation to diagnose
a  rheumatic  aetiology  (RHD)  of  valvular  heart  disease  by  assessing  the  morphological
characteristics of the valves involved.[16] (Table 1) For the mitral valve, leaflet and chordal
thickening,  restricted  leaflet  motion  and  excessive  leaflet  tip  motion  during  systole  are
assessed according to the recommendations. 
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Table 1. Morphological features of RHD as assessed by echocardiography[16]
World Health Federation: Morphological features of RHD
Features in the MV 
■ AMVL thickening* ≥3 mm (age-specific) 
■ Chordal thickening
■ Restricted leaflet motion
■ Excessive leaflet tip motion during systole.
AMVL thickness should be measured during diastole at full excursion. Measurement should
be  taken  at  the  thickest  portion  of  the  leaflet,  including  focal  thickening,  beading,  and
nodularity.  Measurement  should  be  performed  on  a  frame  with  maximal  separation  of
chordae from the leaflet  tissue. Valve thickness can only be assessed if  the images were
acquired at optimal gain settings without harmonics and with a frequency ≥2.0 MHz 
Abnormal thickening of the AMVL is age-specific and defined as follows:
 ≥3 mm for individuals aged ≤20 years; 
≥4 mm for individuals aged 21–40 years;
 ≥5 mm for individuals aged >40 years.
 Valve  thickness  measurements  obtained  using  harmonic  imaging  should  be  cautiously
interpreted and a thickness up to 4 mm should be considered normal in those aged ≤20 years.
Restricted leaflet motion of either the anterior or the posterior MV leaflet is usually the result
of chordal shortening or fusion, commissural fusion, or leaflet thickening.
Excessive leaflet tip motion is the result of elongation of the primary chords, and is defined
as displacement of the tip or edge of an involved leaflet towards the left atrium resulting in
abnormal coaptation and regurgitation. Excessive leaflet tip motion does not need to meet the
standard echocardiographic definition of MV prolapse disease, as that refers to a different
disease process. This feature applies to only those aged <35 years. In the presence of a flail
MV leaflet in the young (≤20 years), this single morphological feature is sufficient to meet
the  morphological  criteria  for  RHD  (that  is,  where  the  criteria  state  “at  least  two
morphological  features  of RHD of  the MV” a flail  leaflet  in a  person aged ≤20 years  is
sufficient). 
Abbreviations: AMVL,  anterior mitral valve leaflet;  AV,  aortic valve; MV,  mitral valve;
RHD: Rheumatic heart disease
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Rheumatic  heart  disease  remains  the  main  cause  of  cardiac  morbidity  and  mortality  in
children and young adults, the predominant mode of death being heart failure. This notably
occurs  in  the  presence  of  a  hemodynamically  severe  valve  lesion,  most  often  mitral
regurgitation.[10,17]  Heart  failure  is  a  very  late  sequela  of  mitral  regurgitation.  Patients
tolerate  severe regurgitation for years before symptoms become evident,  when surgery is
usually required.  The timing of surgical intervention in mitral regurgitation becomes more
difficult when regurgitation is severe and patients have minimal or no symptoms. In general,
surgery  is  performed  in  asymptomatic  patients  with  mitral  regurgitation,  when  there  is
evidence of an increase in ventricular size indicating myocardial decompensation.[8,18,48]
Surgical correction of the regurgitant valve results in left ventricular reverse remodelling and
improvement  of  heart  failure.   This  suggests  that  the  underlying  myocardial  factor  in
rheumatic MR is reversible.[10,17]
Current recommendations for surgical intervention as per International guidelines include all
symptomatic patients with severe chronic MR (Class I, level of evidence B), asymptomatic
patients with left ventricular dysfunction LVESD≥45mm and/or EF≤60% (Class I, level of
evidence B) or asymptomatic patients without LV dysfunction but with the presence of atrial
fibrillation or pulmonary hypertension -PASP at rest>50mmHg (Class IIa, level of evidence
B).[8]  (Tables  2-4)  Surgery  may  be  undertaken  if  it  is  deemed  to  benefit  the  patient  in
instances  of  severe LV dysfunction  (EF<30%) where the patient  is  refractory  to  medical
therapy, but has low co-morbidity and high rates of successful mitral valve repair. (Figure 1)
15
Table 2. Indications for intervention in severe primary mitral regurgitation[8]
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Table 3. Classes of recommendations[8]
Table 4. Levels of evidence[8]
*Tables 2-4, adapted from 2017 ESC/EACTS Guidelines for the management of valvular 
heart disease
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Figure 1. ESC algorithm for management of severe chronic primary MR[8]
*Figure 1, adapted from 2017 ESC/EACTS Guidelines for the management of valvular heart 
disease
In review of the literature, most patients with left ventricular dysfunction are usually more
symptomatic  and  have  a  tendency  toward  unfavourable  post-operative  clinical  and
echocardiographic  results.[19,20,21,51]  Tribouilloy  et  al  showed that  patients  with  larger
LVESD had more symptoms and a higher frequency of atrial fibrillation. They concluded that
LVESD >40mm independently predicted higher mortality in patients  who were medically
managed as well as in those who underwent mitral surgery.[19] Similarly, Wisenbaugh et al
studied 66 patients  with mostly  rheumatic  MR who underwent  mitral  valve replacement.
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Their study demonstrated that the probability of death or heart failure increased abruptly at a
pre-operative LVESD of 51mm, and that a pre-operative LVESD of 40mm was associated
with good outcome. Taking these observations into account, the recommended optimal time
for surgery was derived at an LVESD between 40 and 50mm.[22]
Suri et al conducted a retrospective study of patients who underwent mitral valve repair or
replacement  for  mitral  regurgitation  resulting  from  leaflet  prolapse.  They  examined  the
medical  records  of  1063  patients  from 1980  to  1999,  which  satisfied  inclusion  criteria.
Demographic data, functional class, presence of atrial fibrillation, decade of surgery (1990s
vs  1980s),  and  history  of  preoperative  myocardial  infarct  or  CABG  was  recorded.[23]
Echocardiographic data (EF, LVEDD, LVESD and left atrial size) was noted pre-operatively,
at predismissal, 1 year or less, 1 to 3 years, and 3 to 5 years. In their study, ejection fraction
declined from the pre-operative to the predismissal value but showed significant recovery at
post-operative follow up. The LVEDD showed steady decline over the follow up periods and
LVESD showed significant reduction between the predismissal time point and the 3 to 5 year
follow up. Suri et al demonstrated that the predictors of preserved left ventricular function
following  mitral  valve  repair  were  pre-operative  EF>65% or  LVESD<36mm  (p<0.001).
However, these factors could not predict recovery for subjects who underwent mitral valve
replacement (p<0.31 for EF and p<0.07 for LVESD).[23] 
In  1994,  Enriquez-Sarano et  al  reported  on a  retrospective  analysis  of  409 patients  who
underwent corrective surgery for organic mitral regurgitation. Multi-variate analysis showed
that  age>75years  (p  .0003)  and  functional  class  (p  .016)  were  predictors  of  operative
mortality  and ejection  fraction  was a  predictor  of  late  survival  (EF>60% associated  with
100% expected survival at 10 years).[24] Functional class NYHA I-II was associated with
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better outcome in the EF>60% cohort as compared to NYHA III-IV (p .0021).[24] In another
study  the  same authors  analyzed  the  pre-operative  echocardiographic  predictors  of  post-
operative  LV  dysfunction  in  266  patients.  Multivariate analysis  showed  that  the  most
powerful  predictor  was  pre-operative  EF  (p  .0001)  followed  by  end  systolic  diameter
(p .0005).[25] Both studies outline the need for mitral valve surgery in patients with chronic
MR prior to the development of left ventricular dysfunction and suggest that clinical and
echocardiographic parameters should be carefully monitored to determine the optimal time
for surgery. 
Because of the inherent limitations of using EF as a marker, several other measures of LV
contractile function have been studied. These include exercise haemodynamics, end systolic
diameter, end systolic wall stress, Doppler derived dP/dt (rate of rise of LV pressure) and
more  recently  LV  strain  parameters.[20,26-30,55]  The  measurement  of  LV  contractile
reserve with exercise echocardiography prior to MVR in patients with chronic nonrheumatic
MR has been shown to be a better predictor of post-operative LV dysfunction (EF<50%).[26]
A 4% decrease in EF had a specificity of 75% and sensitivity of 79%.[26] In 2005, Lee et al
also reported that an intact contractile reserve predicts preserved post-operative LV function.
[27]. However, bearing in mind the caveats, in clinic practice simple estimation of the EF
provides reasonable estimation of LV function in the majority of cases [43], but fails to detect
which patients will have impaired LV function postoperatively.
Although left atrial size has not been identified as a predictor of post-operative outcomes in
patients with chronic MR, it has been found to reflect the severity and duration of the MR.
[31,32] Both left atrial size  and PASP are significant predictors of cardiac related mortality.
[32,33] Barbieri et al reported the presence of significant pulmonary hypertension (as defined
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by PAS>50mmHg at  rest)  in  20% to 30% of  patients  with  severe  MR.[33]  Multivariate
analysis showed that older age and larger LA size were associated with a higher prevalence
of  pulmonary  hypertension  (p<0.0001).[33]  The  presence  of  pulmonary  hypertension
depends on the severity of MR, the functional class of the patient and the presence of LV
dysfunction.[34,35,52] Yang et al reported that the presence of pulmonary hypertension in
patients  with  primary  MR  with  preserved  preoperative  EF  predicted  post-operative  LV
dysfunction (EF<50%).[36] 
Tricuspid regurgitation is common accompaniment in MR. Sani et al showed a prevalence of
tricuspid regurgitation as a complication of rheumatic heart disease in 30.2% of 129 patients.
[37]  To  what  extent  tricuspid  regurgitation  affects  the  outcome  in  patients  with  chronic
rheumatic  MR has  not  been  clearly  established.[39]  In  chronic  rheumatic  MR tricuspid
regurgitation  may  be  secondary  to  left  heart  dilation  and dysfunction,  concomitant  atrial
fibrillation,  pulmonary  congestion  and  pulmonary  hypertension  with  subsequent  right
ventricular dilation, and less commonly, it is due to rheumatic involvement of the tricuspid
valve.[577] The entity of late TR that develops years after mitral valve surgery may be due to
prosthetic  valve dysfunction,  left  heart  disease,  right  ventricular  dysfunction and dilation,
pulmonary hypertension, atrial fibrillation, and tricuspid annular dilation.[38,39] As tricuspid
regurgitation in mitral valve disease portends a poor outcome, resulting in right heart failure
and reduced functional  capacity,  it  is recommended that  tricuspid annuloplasty should be
performed at the time of mitral surgery if the tricuspid annulus measures more than 35mm.
[39]
In addition to preoperative parameters, the cardiopulmonary bypass time (CPBT) has also
been to shown to predict post-operative outcome in patients undergoing MVR. In a study
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performed by Salis et al, which involved 5006 patients between 2002 and 2008, the mean
CPBT was found to be 115 minutes.[43] Multivariate analysis showed that CPBT, considered
in 30 minute increments, was significantly associated with postoperative death; pulmonary,
renal and neurologic complications; multi-organ failure; and multiple blood transfusions.[44]
Madhavan et al calculated that total CPBT should be kept to less than 180 minutes in order to
minimize  postoperative  morbidity  and  mortality.[45]  This  was  in  contrast  to
recommendations by Nissinen et al in 2009 who advocated 240 minutes.[46] The consensus
is that a shorter CPB duration is associated with improved outcomes.
In summary, multiple studies have been conducted with the aim of determining clinical and
echocardiographic predictors  of postoperative left  ventricular  dysfunction in subjects with
chronic MR, in order to inform timely surgical intervention and improved outcomes. This
study describes clinical and echocardiographic characteristics in patients undergoing MVR
for severe rheumatic MR in the province of KwaZulu-Natal and examines the response of the
left ventricle after surgery using serial echocardiographic analyses. 
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EFFECT OF MITRAL VALVE REPLACEMENT ON LEFT VENTRICULAR 
FUNCTION IN SUBJECTS WITH SEVERE RHEUMATIC MITRAL 
REGURGITATION 
INTRODUCTION
Recent hospital-based studies in South Africa (SA) reveal an incidence of congestive heart
failure secondary to RHD of 25 cases/100 000/year.[1,2] Mitral regurgitation (MR) is one of
the commonest causes of heart failure in subjects with RHD. Subjects with MR may remain
asymptomatic for many years and those with severe MR may only develop symptoms after 6
to 10 years. Symptoms occur late in the natural history of chronic MR since the left atrium
dilates to allow it to accommodate large volumes of blood without a significant rise in left
atrial pressure.[3] As the lesions of MR progress, left ventricular volume overload ensues as a
result of the increase in the regurgitant orifice area.[4] Long standing severe MR eventually
leads  to  impaired  LV  function  with  increasing  endsystolic  volumes  and  pulmonary
congestion.  Although  there  may  be  underlying  LV  dysfunction,  ejection  fraction  is
maintained until late in the disease process.[4] 
At the point when the end systolic diameter increases to above 40mm the EF falls below
60%.[4] International guidelines therefore recommend surgical intervention when the patient
develops  dyspnoeic  symptoms,  and/or  echocardiography  demonstrates  evidence  of  left
ventricular dysfunction (EF < 60%) and/or dilatation (ESD > 45mm).[4,5] 
Suri  et  al  demonstrated  that  the  predictors  of  preserved  left  ventricular  function  post-
operatively were pre-operative EF>65% or LVESD<36mm.[6] An EF less than 60% has been
31
shown to be associated with poorer survival rates after corrective surgery and is likely to
indicate  contractile  dysfunction  in  MR  patients.[7]  Tribouilloy  et  al  showed  that  left
ventricular  ESD  >40mm  independently  predicted  higher  mortality  in  patients  who  were
medically  managed  and  after  mitral  surgery.[8]  Since  most  patients  with  left  ventricular
dysfunction are usually more symptomatic and are more likely to have an unfavourable post-
operative clinical outcome the management of chronic MR demands careful surveillance by
the clinician to detect early changes that indicate the need for surgery.[5]
In  developing countries, difficulty in access to health care as well as a resource-restricted
state  health  service  result  in  many subjects  escaping detection  due to  the  very nature  of
compensatory  haemodynamics  in  MR,  and  account  for  later  presentations  in  the  natural
history of  MR. A recent  study of a cohort  of patients  with severe MR at  Inkosi Albert
Luthuli Central Hospital (IALCH), a tertiary institution in Kwazulu-Natal, South Africa, has
shown that patients with severe mitral regurgitation frequently presented late; many were in
heart  failure,  beyond  the  optimal  period  for  surgical  intervention  as  judged  by  the
echocardiographic parameters and confirmed on natriuretic peptide estimation.[9]  However,
this study did not describe the outcome of subjects undergoing surgery for rheumatic MR
who have impaired LV function, since few patients had overt impairment of LV function [9].
We  hypothesized  that  in  these  subjects  recovery  of  contractile  function  is  slow  with
persistence  of  heart  failure  symptoms.  Since  these  subjects  are  known to  have  a  poorer
prognosis [7] and reduced survival rates [8] we examined the clinical and echocardiographic
variables in subjects with severe rheumatic MR who underwent MVR in order to define the
early surgical outcome in those with impaired LV function, and evaluate the response of the
left ventricle after corrective surgery.
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METHODS
This retrospective study was conducted in subjects with severe rheumatic MR confirmed at
echocardiography in the Department of Cardiology at Inkosi Albert Luthuli Central Hospital
(IALCH)  over  a  nine  year  period  (2005  -2013).  Patients  were  selected  using  the  CPT
(Common  procedural  terminology)  code  for  mitral  valve  replacement  (33430)  via  the
Speedminer  software  program  3  (Speedminer  Malaysia),  which  is  a  Data  Warehouse
Management software package, used at IALCH to record and categorise patients’ medical
details.  Patient  demographics,  HIV  status,  New  York  Heart  Association  (NYHA)
classification,  presence  of  atrial  fibrillation,  chronic  medication,  and  echocardiographic
parameters were recorded at their most recent pre-operative visit and subsequent to MVR at 2
weeks, 6 weeks to 3 months and 6 months to 2 years follow up intervals. Data was collected
and grouped according to pre-operative EF in each case: EF<40%, EF 40-49%, EF 50-59%
and EF>60%.
Patients with pure rheumatic mitral regurgitation were included. Patients with ischaemic and
functional MR, concomitant mitral stenosis with mitral  valve area (MVA) <2.5cm², aortic
valve disease, congenital heart disease, previous MV surgery or other cardiac surgery were
excluded.  Surgical  operative  notes  were  further  scrutinized  to  determine  mitral  valve
pathology and document cardiopulmonary bypass times (CPBT).
Two dimensional directed m-mode and colour Doppler echocardiography was performed on
all  patients  using  a  Siemens  Sequoia  machine  (Acuson,  Germany)  with  a  phased  array
transducer and an emission frequency of 3.0 megahertz with the patient in the left decubitus
position. Images were obtained according to a standardised protocol. The left ventricular end-
systolic (LVESD) and end-diastolic dimensions (LVEDD), left atrial (LA) size, pulmonary
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artery systolic pressures (PASP) and the presence and severity of tricuspid regurgitation (TR)
were  measured  according  to  the  American  Society  of  Echocardiography  (ASE)  chamber
guidelines.[10] Ejection fraction (EF) was assessed using the Simpson’s method.[10]
Mitral regurgitation was considered to be rheumatic in aetiology when the morphology of the
valve  satisfied the  proposed World  Heart  Federation  (WHF) criteria  for  the  diagnosis  of
chronic RHD.[11] Clinical evaluation of the severity of MR in this unit was supported by
colour Doppler estimation of the regurgitant jet into the left atrium, the Doppler intensity of
the  regurgitant  envelope,  and  the  left  atrial  size  using  qualitative  and  semi-quantitative
methods  as  per  ASE  and  European  Society  of  Cardiology  (ESC)  valvular  regurgitation
guidelines.[10,12] Calculation of the effective regurgitant orifice using Proximal Isovelocity
Surface Area (PISA) was not done because in most cases the regurgitant flow into the left
atrium was characterised by an eccentric jet.  
The  clinical  endpoints  of  this  study  were  to  establish  whether  impaired  left  ventricular
function, as measured by preoperative EF<60%, was associated with a poor surgical outcome
in respect of increased rates of mortality and persistent heart failure postoperatively. We also
sought  to  determine  which  other  preoperative  echocardiographic  parameter/s  (LVEDD,
LVESD,  LA and/or  PASP)  could  predict  post-operative  left  ventricular  dysfunction  and
measured  the  changes  in  these  echocardiographic  parameters  at  follow  up.  Comparison
between the pre- and postoperative NYHA class was drawn to determine whether surgery
improved functional disability and symptoms.
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Statistical analysis
Statistical  Package for the Social  Sciences (SPSS version 23.0) (IBM, Los Angeles)  was
utilized in the analysis of data for the study. A 95% level of confidence interval (CI) was
estimated, and a global significance level of ά = 5% was chosen, to test for the assumptions
of  the  null  hypothesis.  Simple  descriptive  analysis  was  used  to  highlight  clinical
characteristics and results were presented as frequencies, means and percentages. Continuous
variables are expressed as means ± standard deviations (SDs).  The student’s t-tests and the
chi-square  tests  were  used  to  compare  continuous  variables  and  categorical  variables
respectively. Paired samples were used to compare changes in echocardiographic variables
before and after surgery. A p value of < 0.05 suggested statistical significant findings for the
variables  being  measured.  Logistic  regression  analysis  was  used  to  identify  preoperative
predictors of impaired LV function (EF < 50%), and included CPBT as a potential factor
associated with post-operative LV dysfunction.
Ethics 
The protocol  (Appendix I),  was approved by the Biomedical  Research Ethics  Committee
(BREC, BE 055/14). Permission was obtained from the University of Kwazulu-Natal, the
Provincial Health Research Committee and Inkosi Albert Luthuli Central Hospital (IALCH)
where  the  data  was  to  be  collected  (Appendices  III-V,  VII).  Patient’s  identities  were
protected as each hospital number was assigned to an ordered numerical system on Microsoft
Excel spreadsheets and these records were only available to the principal investigator and
supervisor. Data from each file was then recorded following the numerical system and this
was made available to the statistician.
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RESULTS
Demographic and clinical data. (Table 1)
During the nine year period 788 subjects underwent surgery for severe MR. Based on the
inclusion criteria a total of 656 patients were excluded. The exclusions comprised subjects
with concomitant  aortic stenosis (11%), aortic regurgitation (39%), mitral  stenosis (75%),
ischaemic MR (4%) and congenital heart disease (3%). This left 132 patients with chronic,
severe, isolated MR who were enrolled into the study. There were 97 females (73%) and 35
males.  Eighty three percent of patients (n=109) were under the age of 25. In the 75% of
subjects who were tested 8% (n=11) were HIV infected. Comorbid conditions were present in
13% of the sample (hypertension (5%), diabetes mellitus (2%), asthma (2%), epilepsy (1%)
and Grave’s disease (3%).
At baseline, 66% (n=87) of patients were NYHA functional class III-IV (NYHA III 30%,
NYHA IV 36%). Heart failure was a common mode of presentation and was present in 38%
percent  (n=50)  of  subjects,  and  14%  (n=19)  had  atrial  fibrillation  prior  to  operative
intervention.  Medication prescribed to the patients in the study included diuretics  (92%),
ACE-I  (95%),  β-blockers  (8%),  calcium  channel  blockers  (2%),  digoxin  (21%)  and
penicillin (72%). 
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Table 1. Baseline Demographic and clinical data 
 EF Group  
 40-49% 50-59% >60% Total
 (n = 7) (n = 30) (n = 95) (n = 132)
 n % n % n % n %
Age group         
<12 yrs 1 14% 3 10%
3
9 41% 43 33%




2 44% 66 50%
>25 yrs 2 29% 7 23%
1
4 15% 23 17%
Sex         
Male 2 29% 7 23%
2





9 73% 97 73%





1 64% 88 67%
Positive 1 14% 3 10% 7 7% 11 8%
Not known 2 29% 4 13%
2
7 28% 33 25%
NYHA class         
I 0 0% 1 3% 9 9% 10 8%
II 1 14% 9 30%
2
5 26% 35 27%
III 2 29% 8 27%
2





2 34% 48 36%










3 66% 82 62%
AF         
Present 1 14% 4 13%
1





1 85% 113 86%
AF, atrial fibrillation; EF, ejection fraction; NYHA, New York Heart Association.
            Only 23 subjects were over the age of 25 years. The majority were HIV negative.
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Pre-operative echocardiographic data (Table 2)
For the entire group, the median EF was 63% (IQR 58-70%), mean LVEDD 60.7±7.9mm,
LVESD 39.9±7.2mm, and LA size 61.2±12.6mm. The median PASP was 59.5mmHg (IQR
45-80mmHg). 
Pre-operatively, 84% of patients (n=111) had an EF>55% and the remaining 16% (n=21) had
an EF<55%. Five percent (n=7) of patients had an ejection fraction (EF) between 40-49%
(median EF 42%, IQR 40-45%) and 23% (n=30) had an EF between 50-59% (median EF
56%, IQR 55-57%). The remaining 72% (n=95) had an EF > 60% (median EF 65%, IQR 62-
70). In all, 28% of subjects had an EF<60% (p<0.001). 
The LVEDD was 62.6±6.5mm in the EF 40-49% group (n=7), 64.3±8.3mm in the EF 50-
59% group (n=30) and 59.4±7.6mm in the EF > 60% group (n=95). The left ventricle was
significantly  more  dilated  in  the  EF  40-59% group  as  compared  to  the  EF>60% group
(p<0.001). The LVESD was 49±6.6mm in the EF 40-49% group (n=5), 46.4±5.8mm in the
EF 50-59% group (n=25) and 37.5±5.9mm in  the  EF>60% group (n=88).  Similarly,  the
LVESD was significantly higher in the EF 40-59% group compared to the EF>60% group
(p<0.001).
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The left atrium was over 55mm in diameter across all three groups. It was 56.3±9.7mm in the
EF 40-49% group (n=7), 65.3±13.8mm in the EF 50-59% group (n=30) and 60.2±12.1mm in
the EF>60% group (n=91) (p=0.09). The pulmonary artery systolic pressures (PASP) were
elevated in all three groups. The median PASP was 50mmHg (IQR 38-53mmHg) in the EF
40-49% group  (n=7),  61mmHg in  the  EF  50-59% group  (IQR 35-79mmHg,  n=29)  and
60mmHg (IQR 47-80mmHg, n=90) in the EF>60% group (p=0.2). Moderate to severe TR
was present in all 7 subjects in the EF 40-49% group, 62% of those in the EF 50-59% group
and in 58% of those with the EF>60%.








LVEDD (mm) 62.6±6,5 64.3±8,3 59.4±7,6  < 0.001
LVESD (mm) 49.0±6,6 46.4±5,8 37.5±5,9  < 0.001
LA (mm) 56.3±9,7 65.3±13,8 60.2±12,1 0,090
EF (%)* 42(40-45) 56(55-57) 65(62-70) <0,001
PASP (mmHg)* 50(38-53) 61(35-79) 60(47-80) 0,200
*  median(IQR)  EF,  ejection  fraction;  LA,  left  atrium;  LVEDD,  left  ventricular  end  diastolic  dimension;
LVESD,  left  ventricular  end  systolic  dimension;  PASP,  pulmonary  artery  systolic  pressure
Chamber dimensions were increased in those with EF < 60%.       
Most patients responded well to surgery with improvement in NYHA functional class (Table
3). At 6 months to 2 years following MVR (n=93), 1% of patients were NYHA III-IV, 1% of
patients had heart failure, and 7.6% had atrial fibrillation.
Table 3. Pre and Postoperative functional class 
Pre-operation Post-operation
6 months – 2 years
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n (132) %   n(93) %
NYHA
I 10 7.6 79 84.9
II 35 26.5 13 14.0
III 39 29.5 1 1.1
IV 48 36.4 0 0.0
NYHA, New York Heart Association, Significant improvement was noted in functional class after surgery 
Operative findings
The patients’ operative notes were studied to determine the macroscopic pathology of mitral
valve  disease  as  described  by  the  cardiothoracic  surgeon.  (Fig.  1)  All  valves  displayed
varying  degrees  of  rheumatic  involvement  as  assessed  by  valve  thickness  and  /or
calcification. Fifty two percent of patients (n=69) had features of isolated chronic MR with
no other findings. In addition to chronic MR, the remaining subjects also had chordal rupture
(23%, n=31), chordal elongation (16%, n=21), active carditis (1.5%, n=2) and one subject
had both chordal rupture and elongation (1%). Chordal elongation was highly suggestive of
active carditis in 21 patients. Chordal rupture was also presumed evidence of active carditis
in young subjects in the absence of infective endocarditis. The surgeon also reported active
carditis  in  two  patients  in  whom  the  pericardium  was  adherent  due  to  adhesions  from
fibrinous  pericarditis.  Two  patients  (1.5%)  had  infective  endocarditis,  both  of  whom
presented in heart failure with EFs > 55%. (Table 4) The first patient, a 23 year old male was
found to have grossly impaired LV function (EF 18%) at the 2 week and 6 weeks to 3 months
follow up visits and was lost to follow up thereafter. The second, an 18 year old female, had
an EF of 70% which fell to 40% at two weeks and she was well (NYHA I) with no clinical
features of cardiac failure at 2 years. 
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Active carditis was reported by the surgeon when the pericardium was adherent due to adhesions from fibrinous
pericarditis,  and /or  chordal  elongation was  present  and /or  chordal  rupture  was present  in  the  absence  of
infective endocarditis.
Outcomes
1. Postoperative morbidity and mortality 
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Despite being in heart failure the majority of patients underwent uneventful surgery with a
median  CPBT was 77 minutes  (n=111,  IQR 64-105 minutes).  Of the  12 patients  with  a
persistently low EF (<50%) at the 6 months to 2 year follow up visit, the median CPBT was
98  minutes  (IQR 80-106  minutes,  p  0.07)  and  was  not  significantly  different  from  the
remaining patients. 
Only 1 out of 94 patients that returned for follow up between 6 months and 2 years post-
operatively, remained in heart failure. Despite a pre-operative EF of 56% in this patient, there
were  already  measurements  indicating  cardiac  chamber  enlargement,  notably  a  markedly
dilated LA of 67mm. At 2 weeks postoperatively, EF was 30% and steadily reduced at the
subsequent follow up visits with concomitant increase in left heart chamber dimensions.
In total, there were five postoperative deaths yielding a mortality rate of 4%. (Table 4) These
deaths occurred in young patients with advanced NYHA class, grossly dilated left atria (n=2)
and  PASP>50mmHg  (n=3).  There  was  no  evidence  of  infective  endocarditis  or  active
rheumatic carditis at surgery. One patient who had a low preoperative EF of 40%, was HIV
infected and demised from lobar pneumonia and cardiac failure two weeks after operation.
Two patients were in extremis preoperatively, required cardioversion in theatre and demised
from a low cardiac output state. The 21yr old male had a good immediate surgical outcome
and died from cardiac tamponade a month later. The last patient was a child who died of
massive air embolism following removal of the aortic cross clamp.  











D ESD LA PAS TR
24 F III Y N 40 66 52 51 49 severe - chronic MR
13 F IV Y N 58 69 - 54 30 severe 68 chronic MR
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20 F IV Y Y 62 66 43 78 69 severe 80 chronic MR
21 M III N Y 68 60 37 77 51 moderate 47 chronic MR
9 F II N N 45 53 29 - 60 - 175 chronic MR
AF atrial fibrillation, CPBT cardiopulmonary bypass time, EDD end diastolic dimension, EF ejection fraction, 
ESD end systolic dimension, F female, HF heart failure, LA left atrium, M male, MV mitral valve, NYHA New 
York Heart Association, PAS pulmonary artery systolic pressure, TR tricuspid regurgitation
2. Profile  and Outcomes in Preoperative Ejection Fraction Subgroups 
A subset of 14 patients had a dramatic reduction in EF in the early postoperative period at the
2 weeks review to less than 30%. (table 5)






HF AF EF EDD ESD LA PAS TR
MV
Pathology
13 F IV Y N 43 62 45 50 50 severe 150 chronic MR
24* F III Y N 40 66 52 51 49 severe - chronic MR
40 F II N N 55 66 43 64 41 mild 60 chronic MR




11 M II N N 56 66 46 78 64 - 165 chronic MR




40 M III N Y 53 79 56 88 79 moderate 85 chronic MR
13* F IV Y N 58 69 - 54 30 severe 68 chronic MR
13 F IV Y N 58 59 - 56 84 severe 40 chronic MR
14 F II N Y 65 78 51 80 63 mild - unknown
27 F II N Y 67 66 44 84 53 moderate 40 chronic MR








16* M IV Y Y 70 65 45 70 74 severe 115 chronic MR
*Deaths, AF atrial fibrillation, CPBT cardiopulmonary bypass time, EDD end diastolic dimension, EF ejection 
fraction, ESD end systolic dimension, F female, HF heart failure, LA left atrium, M male, MV mitral valve, 
NYHA New York Heart Association, PAS pulmonary artery systolic pressure, TR tricuspid regurgitation
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Most patients were in advanced NYHA class and had EF < 60%, ESD > 44mm with markedly dilated LA size. 
Of these, two thirds (n=9) had a preoperative EF <60% (2 had EF 40-49%), eight patients had
clinical features of heart failure (NHYA IV, n=7) and 5 were in atrial fibrillation. (Table 4)
Average CPBT in these patients was calculated to be 101 minutes (range 40-180 minutes).
Eight patients received inotropic support at the end of mitral  valve surgery. Two patients
were HIV infected: one had a pre-operative EF of 40% and demised 2 weeks after MVR, and
the other had a pre-operative EF of 55% and made an uneventful recovery. In this subset of
14 patients, 5 patients recovered their EF to more than 50% at 6 months to 2 years follow up
(pre-operative EF, median 65, IQR 58-67); three died  and six were lost to follow up. 
i. Pre-operative EF 40-49% group (n=7) (Table 6)
Except for two who were middle aged, these were young patients who were in heart failure
with moderate  to severe tricuspid regurgitation.  One was HIV infected and as mentioned
earlier,  demised  from lobar  pneumonia  2  weeks  after  surgery.  In  three  patients  the  EF
recovered (52, 56, and 59%) and was accompanied by fall in the LVESD and resolution of
TR at 6 months to 2 years (Table 7); the remaining three patients were lost to follow up. 
Table 6. Preoperative Profile of Patients with preoperative EF 40-49%  
Age M/F Co-morbidities NYHA
HF AF Echo
Y/N Y/N EF EDD ESD LA PAS TR
15 M Grave’sdisease IV Y N 40 65 51 57 37 moderate
13 F nil IV Y N 43 62 45 50 50 severe
57 F HPT IV Y N 42 73 57 70 52 severe
6 M nil III N N 49 53 40 41 83 severe
19 F nil IV Y N 40 62 - 63 38 severe
48 F HPT II N Y 45 57 - 62 53 severe
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24* F PIH III Y N 40 66 52 51 49 severe
*HIV infected subject who died at two weeks from lobar pneumonia 
AF atrial fibrillation, EDD end diastolic dimension, EF ejection fraction, ESD end systolic dimension, F female,
HF heart  failure, HPT   hypertension, LA  left  atrium,  M male,  MV mitral  valve,  NYHA  New  York  Heart
Association,  PAS pulmonary  artery  systolic  pressure,  PIH   pregnancy  induced  hypertension,  TR  tricuspid
regurgitation
Table 7. Follow-up echocardiographic data in subjects with preoperative EF 40-49%
Pre-operation Post-operation
2 weeks 6 weeks - 3 months 6 months - 2 years
LVEDD (mm) 62.6±6,5 57.3±5,9 58.7±15          59±19,8
LVESD (mm) 49.0±6,6 - 35.0±1,4 40.5±13,4
EF (%)* 42(40-45) 43(18-48)      52.0(10-54)    56.0(52-59)
LA (mm)      56.3±9,7  42.4±6,3           58.0±0          61.5±19
PASP (mmHg)* 50(38-53) 45(37-62)     62.0(40-64)    43.5(35-52)
* median(IQR) EF, ejection fraction; LA, left atrium; LVEDD, left ventricular end diastolic dimension;               
LVESD, left ventricular end systolic dimension; PASP, pulmonary artery systolic pressure 
ii. Pre-operative EF 50-59% group (n=30). (Table 8)
After an immediate fall in the EF to 40% (IQR 30-46%, n=30) at two weeks, it rose steadily
to 56% (IQR 47-59%, n=19) at 6 months to 2 years follow up. Moderate to significant TR
was present in 62% of patients pre-operatively, in 52% at 2 weeks and 56% at 6 weeks to 3
months. At 6 months to 2 years post MVR only 13% had significant TR. After the initial
decrease in echocardiographic parameters at two and six weeks, further decreases became
apparent at the 6 month to 2 year visit with significant reduction in LVEDD, LVESD, LA and
PASP between the preoperative and 6 month to 2 year follow up visit. (all p<0.001).
Table 8. Follow-up Echocardiographic data in subjects with baseline EF 50-59%
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Pre-operation Post-operation
2 weeks 6 weeks - 3 months 6 months - 2 years
LVEDD (mm) 64.3±8,3 56.0±8,7 55.3±10,1          49.0±9,6
LVESD (mm) 46.4±5,8 41.5±6,8 39.8±10,4 36.0±10,9
EF (%)* 56(55-57) 40(30-46)   50.0(28-53)   56.0(47-59)
LA (mm) 65.3±13,8 51.0±13,4 49.3±11,8 44.6±12,4
PAS (mmHg)* 61(35-79) 46.5(35-55)   43.0(37-46)   34(28,5-40)
* median(IQR) EF, ejection fraction; LA, left atrium; LVEDD, left ventricular end diastolic dimension;              
LVESD, left ventricular end systolic dimension; PASP, pulmonary artery systolic pressure
iii. Pre-operative EF>60% group (n=95) (Table 9)
There was an immediate fall in the EF from 65% (IQR 62-70%) preoperatively to 47.5%
(IQR 40-57%, n=92) at two weeks (p<0.001); thereafter it increased to 56% (IQR 48.5-60%,
n=48) at 6 weeks to 3 months and remained stable at 57% (IQR 43-65%, n=63) at 6 months
to 2 years (p<0.001). In this group all other parameters steadily reduced over all three time
points analysed but most of the decline in LV chamber dimensions appeared complete at the
six weeks and remained stable at six months. The LA size and PASP continued to decrease at
the six month evaluation. There were significant reductions for LVEDD, LVESD, LA and
PASP from the preoperative evaluation to the follow up at 6 months to 2 years (all p<0.001).
Moderate to severe TR was present in 58% of patients pre-operatively, was present in 31% at
6 weeks to 3 months, and remained in 28% at 6 months to 2 years. 
Table 9. Follow–up echocardiographic data in subjects with baseline EF >60%
Pre-operation Post-operation
2 weeks 6 weeks - 3 months 6 months - 2 years
LVEDD (mm) 59.4±7,6 51.3±7,7 46.5±7,4 48.2±7,4
LVESD (mm) 37.5±5,9 36.2±9,8 32.5±9,4 31.8±6,4
EF (%)* 65(62-70) 47.5(40-57) 56.0(48,5-60) 57.0(43-65)
LA (mm) 60.2±12,1 49.0±11,4 43.9±9,1 42.6±8,7
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PASP (mmHg)* 60(47-80) 45.0(38-55) 41.5(36-49) 36.5(31-41)
* median(IQR) EF, ejection fraction; LA, left atrium; LVEDD, left ventricular end diastolic dimension;              
LVESD, left ventricular end systolic dimension; PASP, pulmonary artery systolic pressure
Figure 2. Pre- and postoperative echocardiographic data at follow-up 
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LVESD, LVEDD, LA, EF and PASP depicted as per the pre-operative EF groups over the follow up intervals of 
2 weeks, 6 weeks to 3 months and 6 months to 2 years. EF improved steadily in all groups after an initial 
decline in the immediate postoperative phase. Chamber dimensions, LA size and PASP all decreased after 
surgery except in the group with EF 40-49%.
Results of paired analysis of echocardiographic parameters 
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                     EF 40-49%
                     
                     EF 50-59%
                     EF>60%
Paired analysis was conducted on 83 subjects with complete datasets for all time points. This
revealed that 17/72 (20%) subjects who had pre-operative EF>55% maintained their EF at 2
weeks (p<0.001, 95% CI 0.02-0.09); this number increased significantly to 60% (n=53) at 6
months to 2 years (p<0.001, 95% CI 0.1-0.5) (p<0.001). The median EF in this paired sample
was 63% (IQR 58-70%) at pre-operation.  (Table 10) At 2 weeks post MVR, there was a
significant  20%  decrease  in  EF  (median  46%,  IQR  38-55)  (p<0.001),  followed  by  a
significant increase to median EF 57% (IQR 52-63%) at 6 months to 2 years visit (p<0.001).
As seen in Table 10, this was accompanied by significant reductions in LVEDD, LVESD, LA
and PASP at 6 months to 2 year follow up.
Table 10. Paired analysis showing change in echocardiographic parameters (n=83)
Pre-operation 6 months - 2 years Change p value
EF (%)*   63(58-70)   57(52-63) -5 < 0.001
LVEDD (mm) 60.2±7,9 48.6±8,3 -11,6 < 0.001
LVESD (mm) 39.9±6,6 33.2±8,4 -6.7 < 0.001
LA (mm) 61.9±10,1 43.7±10,1 -18.2 < 0.001
PASP (mmHg) 63.9±23,4 37.4±8,8 -26,5 < 0.001
* median(IQR) LA, left atrium; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end 
systolic dimension; PASP, pulmonary artery systolic pressure; SD, standard deviation.
Predictors of postoperative LV dysfunction
In  this  study  9/14  subjects  who  had  a  dramatic  decline  in  LV  function  immediately
postoperatively to EF<30% had a preoperative EF <60% and 8 were in severe heart failure,
requiring inotropic support. The 5 subjects who recovered their EF to more than 50% at the 6
month follow up had a median pre-operative EF of 65% (IQR 58-67).  Among the seven
subjects with EF in the 40-49% range only three recovered their EF to > 50%. The remaining
two groups (EF 50-59% and >60%) responded similarly with an initial fall in the EF at two
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weeks and a steady increase thereafter to over 55% in both groups, accompanied by a decline
in chamber dimensions and pulmonary artery pressure. Of significance, most of the recovery
in LV function and chamber diameters was complete at six weeks in the subjects with a
preoperative EF>60%, while the PA pressure continued to fall and normalised at six months.
After feeding all clinical and echocardiographic variables into a predictive model only the 
ESD emerged as a significant predictor of postoperative LV dysfunction (EF< 50%) both on 




Rheumatic heart disease remains the major cause of cardiac morbidity and mortality in young
adults with cardiovascular disease.[13] Most of our subjects (83%) undergoing mitral valve
replacement for severe rheumatic mitral regurgitation were under the age of 25; two thirds
presented with severe functional disability (NYHA III-IV) and over a third were in  advanced
heart failure. Despite this, the overall response to surgery was good: among the 70% who
returned to follow-up at 6 months to 2 years: only 1% of patients had signs and /or symptoms
of heart failure (NYHA III-IV), with almost complete resolution of tricuspid regurgitation.
The finding of persistent TR in the group with preserved LV function suggest the presence of
underlying  organic  tricuspid  valve  disease  in  these  patients  which  was  not  addressed  at
surgery. [15]
Impaired LV function 
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A sobering finding of our study is that 37 (28%) subjects underwent surgery with an EF
under 60% and ESD over 46mm.ie well beyond the established guidelines recommended for
MVR.[5] This  pattern  is  a  frequent  finding in  developing countries  where many patients
present  for  the  first  time  with  poor  prognostic  echocardiographic  parameters  such  as  an
ejection fraction of 60% or an end-systolic diameter of 45 mm. In our paired analysis of 83
patients the majority of subjects had an EF above 55%, which was followed by an immediate
fall in the EF after surgery such that only 20% (n=17) had an EF>55% at 2 weeks follow up
(p<0.001, 95% CI 0.02-0.09), with subsequent improvement to an EF > 55% in 60% (n=53)
at  6  months  to  2  years.  This  suggests  the  majority  of  subjects  had  some degree  of  LV
impairment as reflected by the median post-operative EF of 42% which is probably the true
EF  upon  removal  of  the  low pressure  runoff  into  the  LA  following  valve  replacement.
Despite  this  the  majority  of  subjects  underwent  uneventful  surgery  and  postoperative
morbidity  manifest  by  heart  failure  which  gradually  improved  over  time.  The  five
documented  early  deaths  in  the  study occurred  in  subjects  who presented  to  hospital  in
extremis (n=2) or suffered postoperative complications (n=3).
There  were  significant  differences  in  LVEDD  and  LVESD  values  in  the  respective  EF
groups,  demonstrating  an  increase  in  these  chamber  dimensions  as  EF decreased.  These
findings  suggest  that  there  are  lesser changes  in  left  ventricular  configuration  when  left
ventricular function is preserved in the setting of severe mitral regurgitation. Although we
expected the left atrium not to be as dilated in the presence of higher EF (>60%) as compared
to the other two groups, in this study the LA was similarly dilated in all EF groups, reflecting
both  the  severity  and the  duration  of  mitral  regurgitation  prior  to  operation.[16]  The EF
gradually  improved  after  the  initial  decline  postoperatively  while  the  remaining
echocardiographic parameters: LVEDD, LVESD, LA and PASP, decreased steadily at follow
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up. Among  the seven subjects with EF in the 40-49% range only three recovered their EF to
> 50%, and among those subjects who had a sharp fall in the EF to <30% immediately after
operation, the five subjects who recovered their EF to >50% at the 6 month follow up had a
median pre-operative EF of 65%. It is reassuring that the EF improved steadily, albeit, more
slowly in subjects with mildly impaired LV function (EF 50-59%) compared to those with
preserved  EF  (>  60%).  This  data  implies  that  although  impaired  LV  contractility  is
encountered in the immediate post-operative period, myocardial function generally improves
over  time,  but  only  reached  normality  in  subjects  with  preserved  preoperative  EF,
emphasizing the need for timeous surgical intervention in severe MR. This supports current
guidelines recommending surgery in asymptomatic severe MR as soon as the LV begins to
dilate (ESD >40mm) or the EF approaches 60%.
The  development  of  contractile  dysfunction  and  its  relation  to  the  severity  of  volume
overload in  MR is  still  not  clearly  understood.[13]   It  is  well  recognized that  prolonged
contractile dysfunction eventually becomes irreversible even after the MR is corrected and is
predictive of both congestive heart failure and death.[7] Under these circumstances mitral
valve replacement  is associated with higher morbidity  and mortality  due to advanced LV
impairment.[9] None of our seven patients in the group with the EF 40-49% (median EF
42%) underwent mitral valve repair which is recommended under these circumstances. The
choice of the surgical procedure was dependent on the available expertise at our centre to
carry out MV repair which is technically difficult in RHD compared to non-rheumatic MR.
[13]
In our study the EF decreased significantly from a median of 63% preoperatively to 45%
postoperatively at two weeks.  Our findings showing an immediate decline in EF following
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surgery  is  well  described.[14] In  Enriquez-Sarano’s  study  the  EF  showed  a  significant
reduction  from 58±13% prior  to  mitral  valve  surgery  to  50±14% following  MVR.  [14]
Several mechanisms explain the decline in EF following surgery in our patients. As pointed
out many of these patients had concealed LV dysfunction that was masked by the ventricular
loading conditions in severe MR, characterized by increased preload and reduced afterload
because  of  the  run-off  into  the  low  pressure  left  atrium  during  systole.  These  loading
conditions  change  immediately  after  valve  surgery  when  the  leak  has  been  corrected,
exposing the left  ventricle  to  full  systemic  pressure and unmasking the  true state  of  LV
contractility. This explains the immediate fall in EF that was observed after surgery in our
patients, which improved in most cases by six months.[6] Another possibility is the presence
of underlying coronary artery disease with ischemic LV dysfunction but this was unlikely in
our  subjects  because most  of  them were young Black African  patients.  Furthermore,  the
deleterious effect of ischaemic cardioplegic arrest on the postoperative ejection fraction in
subjects is responsible for a transient decline in the early postoperative ejection fraction and
must be expected in most subjects with MR. The importance of adequate cardioprotection
during cardiopulmonary bypass is a critical factor that cannot be underestimated in subjects
with already compromised LV function from long standing severe MR. Myocardial ischemia
resulting from a longer duration of cardioplegic arrest was reflected in the prolonged CPBT
in our subjects with postoperative LV dysfunction, and no doubt contributed to persistent LV
dysfunction.[29] Lastly Essop has emphasised the importance of preserving the chords at
surgery since any discontinuity in the chordal-mitral apparatus could lead to further dilatation
and  impairment  of  the  left  ventricle  after  surgery,  thus  the  non-practice  of  chordal
preservation may allow for misinterpretation of the postoperative EF. [13] This practice was a
standard procedure during MVR in our subjects.
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Active carditis
An important consideration is the presence of underlying active carditis in young subjects
undergoing MVR. Early studies have shown that heart failure is the predominant mode of
death in rheumatic carditis, explaining the high early mortality rate among young patients
with acute rheumatic carditis.[17,18] Annular dilatation and chordal elongation have been
described  as the main mechanism leading to mitral valve prolapse and severe regurgitation
during active carditis.[17,18] Pure mitral valve regurgitation without stenosis causing heart
failure is common in the young who have severe active rheumatic carditis.[13,19] Evidence
of  active  carditis  characterised  by  pericardial  inflammation,  chordal  elongation  and  /or
chordal rupture was present in 55 (42%) patients and may well explain the impairment in
ventricular  function  in  these  cases.  Early  surgery  is  lifesaving  is  these  patients  and  the
underlying ventricular impairment slowly improves in the majority of cases.[13]
Reason for Late surgery
In contrast to developed countries where MR is primarily due to mitral valve prolapse with/
without chordal rupture or coronary artery disease with underlying myocardial ischaemia, in
sub-Saharan Africa rheumatic heart disease is responsible for the majority of cases of chronic
MR. Because of the compensatory haemodynamics in chronic MR, many of these subjects in
the  developing  world  present  late  in  the  disease  when  symptoms  are  advanced.  This
difference in disease presentation is largely a result of poor socioeconomic circumstances
affecting  both  the  rural  and  peri-urban  communities.  Socioeconomic  challenges  prevent
timely access to care;  these social  inequalities coupled with a resource-constrained health
sector  all  contribute  to  delayed referrals  for  specialist  assessment  and intervention.  As  a
result,  most  of  our  subjects  with  severe  MR received  operative  intervention  when  their
cardiac function has deteriorated beyond the recommended cut-off for surgical intervention
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as  per  international  norms.  Furthermore  over-burdened,  understaffed  and under-resourced
state health institutions contributed to incorrect and delayed diagnoses. These factors led to
delayed  referral  to  the  single  tertiary  centre  in  KZN  (IALCH),  where  bed  and  theatre
constraints  resulted  in  further  delays  before  surgery  was  undertaken.  As  a  result  many
patients presented with severe functional disability, often in heart failure, which impacted on
postoperative  outcomes  and  contributed  to  significant  morbidity  and/or  mortality.
Wisenbaugh et al documented that patients in developing countries may present for the first
time  when  EF<60% or  ESD>45mm.[21]  These  patients  suffer  poor  outcomes  following
mitral  valve  replacement  and would  likely  benefit  from mitral  valve  repair,  albeit  repair
undertaken  in rheumatic disease is technically more difficult than with degenerative MR.[4]
Physician related factors 
A more worrying explanation  for  delayed surgery is  that  clinicians  may not be applying
established guidelines in referring patients more timeously for surgery. The median EF in our
study was 56% suggesting that clinicians are using an EF of 55% to decide on the timing for
valve replacement in severe MR, which is not according to the recognized guidelines for
mitral valve replacement surgery. Patients with moderate-severe MR are assessed by more
junior staff who may not request the echocardiographic assessment because of the demands
of a busy clinic; and because such patients are relatively asymptomatic they may be given
repeated  follow  up  appointments  in  the  assumption  that  all  is  well  in  stable  patients.
Symptoms often occur late in the course of MR since the compliance properties of the left
atrium allow it to accommodate large volumes of blood before a significant rise in pressure is
transferred  to  the  pulmonary  circulation.   With  increasing  severity  of  regurgitation,
contractile dysfunction may supervene, often preceding the onset of dyspnoeic symptoms. An
EF less than 60% has been shown to be associated with poorer survival rates after corrective
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surgery and is likely to indicate underlying contractile dysfunction in MR patients.[3,8,20]
The majority of our patients had markedly enlarged LA sizes (n=84, 66% with LA > 55mm)
and elevated PASP (n=66, 50% with PASP >60mmHg) indicating that these subjects had
severe  chronic  MR  of  sufficiently  long  duration  for  such  advanced  changes  to  have
developed. Chronic MR therefore requires careful monitoring by experienced clinicians with
repeated  echocardiographic  assessments  which  would  reveal  the  onset  of  ventricular
decompensation and the need for early surgery in such cases. 
Timing of surgery
The timing of surgery in patients with severe mitral regurgitation (MR) is a critical factor in
the preservation of myocardial function. Wisenbaugh et al have shown that the preoperative
end-systolic diameter is the only independent predictor of postoperative death.[21] Whereas a
good outcome was predicted at a preoperative end-systolic diameter of 40mm, he showed that
the risk of severe heart failure and/or death sharply increased when it reached 51 mm. Taking
these observations into account, the recommended optimal time for surgery can be derived at
an  LVESD  between  40  and  50mm,  mitral  valve  repair  being  the  preferred  surgical
intervention when LVESD reaches 50mm.[6,8,13] Despite the median EF being 65% and the
median  ESD being 37,5mm in  our  group with  preserved EF (>60%),  these  patients  had
markedly  enlarged  left  atria  (median  > 60mm) and elevated  PASP (median  > 60mmHg)
indicating that they also had severe chronic MR of sufficiently long duration for such changes
to have developed. 
Pulmonary hypertension is another independent predictor of post-operative mortality,  with
the  risk  of  death  or  occurrence  of  heart  failure  being  twice  as  high  as  patients  without
pulmonary  hypertension.[22]  The  presence  of  pulmonary  hypertension  depends  on  the
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severity of mitral regurgitation, the functional class of the patient and the presence of LV
dysfunction.[23,24] Significant pulmonary hypertension (PAS>50mmHg) has been reported
in 20% to 30% of patients with severe MR [22] and 64% of patients with functional class
NYHA III-IV.[23] The preoperative PASP was elevated beyond 50mmHg in all EF groups in
our study and was lowest in the group with significantly impaired LV function (EF 40-49%).
This may be due to an underestimation of the RA pressure in these subjects, most of whom
were in advanced heart failure.
The majority of our patients were symptomatic and were receiving heart failure treatment,
including ACE inhibitors. Controlling symptoms in these patients with medical therapy in the
belief that LV function and cavity size are stable in such patients is a misinterpretation of the
evidence-based guidelines for intervention, which recommend surgery in symptomatic severe
MR regardless of chamber dimensions.[5,26] The current paradigm for managing severe MR
is to offer early surgery in these patients because of the difficulty in diagnosing underlying
left ventricular dysfunction and because the long term outcome may be poor even in subjects
with  good  LV  function  as  assessed  by  the  EF. It  is  already  well  established  that  the
preoperative  EF  does  not  predict  the  long-term  outcome  following  MVR.[26,27]
Furthermore,  operative outcomes have improved considerably with better  cardioprotection
and  also  using  the  technique  of  MV  repair  in  subjects  with  significantly  impaired  LV
function. We did not include subjects with MV repair in our study as the numbers were few
and the operation was not regularly performed at our centre because of the lack of surgical
expertise.
Limitations
This study has several limitations, among them being the retrospective design which resulted
in incomplete datasets for analysis and the use of raw echocardiographic data which were not
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indexed to body surface area. Routine HIV testing prior to surgery was not a prerequisite to
surgery in the early years when 25% were not tested.  HIV infection was present in 8% of
those tested and did not explain the impaired LV function in the group with EF 40-49%.
Although there was a low cardiac-related mortality rate in our study (4%) this may not be a
true reflection of mortality as nearly one quarter of patients failed to return for follow up. The
poor follow-up after the six week visit also resulted in reduced numbers of matched pairs for
comparison, thereby reducing the total number of patients whose data could be interrogated
for statistical purposes. Also, in our study we did not routinely use quantitative measurements
such  as  calculation  of  the  effective  orifice  area  and  regurgitant  fraction  which  are  now
recommended in both sets of guidelines.[4,5] Our cohort of MR did not include patients with
pre-operative EF <40% submitted for MVR as per policy of our surgical unit. 
Conclusion
In this study a significant number of subjects with severe MR had advanced symptoms with
decompensated HF and their echocardiographic parameters were well beyond the guidelines
recommended  for  surgical  intervention.  While  it  is  reassuring  that  operative  intervention
improved cardiac dynamics and LV function in the ensuing 3 to 6 months in subjects with
mildly impaired LV function, a cohort of patients remained with impaired LV function due to
delayed  operation.  The  preoperative  ESD  was  the  only  predictor  of  postoperative  LV
dysfunction. Several factors accounted for surgery being performed in the very late stages of
the  natural  history  of  MR in  our  patients,  among them the  primary  reason being  socio-
economic challenges associated with lack of access to health care as a result  of a failing
public healthcare system.  Chronic organic mitral regurgitation (MR) requires careful clinical
surveillance and prompt referral  for regular  echocardiographic assessment to enable early
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detection of LV dilatation and timeous surgery in order to achieve preservation of ventricular
function.
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Title of study 
Effect  of mitral  valve replacement  on left  ventricular  function in patients  with rheumatic
mitral regurgitation and impaired ejection fraction
Aim of study 
To assess the effect of mitral valve replacement on left ventricular function in patients with
rheumatic mitral regurgitation and impaired ejection fraction
Specific objectives 
 To determine the effect on cardiac function after mitral valve replacement
-  To determine  the  cut-off  point  in  terms  of  pre-operative  ejection  fraction  when
surgery will no longer yield a positive effect
 To determine the effect of pulmonary hypertension on outcome
Background and Literature 
Information from research in the developed countries describe organic mitral regurgitation 
secondary to mitral valve prolapse or flail mitral leaflets as these are the common aetiology.
In sub-Saharan Africa, rheumatic heart disease is a common occurrence although statistics
indicating incidence and prevalence are not known. The difference in spectrum of disease is a
result of poor socioeconomic circumstances. 
As a result of lack of adequate education in the community,  untimely referrals to tertiary
institutions  for  specialist  intervention  and  a  resource-restricted  state  health  care  service,
patients  with severe mitral  regurgitation receive operative intervention when their  cardiac
function has deteriorated beyond the recommended cut-off for surgical intervention as per
international norms.
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Much of research published in the literature and therefore the derived outcome and guidelines
for  mitral  regurgitation  pertains  to the developed countries.  Inasmuch as  the aetiology is
different, the pathological processes are similar.
Mitral  regurgitation results in an increased preload and volume of blood entering the left
ventricle.  The  left  ventricle  hypertrophies  to  compensate  which  maintains  the  ejection
fraction at greater than 60%. As mitral regurgitation persists and worsens, the left ventricle
dilates due to oxidative damage to the myocytes as well as left ventricular remodelling. At
this point, the end systolic diameter increases to above 40mmHg and the ejection fraction
falls below 60%. 
According to the American College of Cardiology/American Heart Association guidelines of
2006, patients with severe mitral regurgitation should undergo operative intervention when
they become symptomatic, or when echocardiogram demonstrates impaired left ventricular
function  (ejection  fraction  <  60%)  and  left  ventricular  dilation  (end-systolic  diameter  >
40mmHg). 
Studies by Tribouilloy et al and Suri et al in 2009, and Stevens et al in 2012 indicate poor
outcomes  when  surgery  is  delayed.  Tribouilloy  et  al  showed  that  left  ventricular  ESD
>40mmHg independently predicted higher mortality in patients who were medically managed
and  in  those  who received  surgery.  Invariably,  post-operative  ejection  fraction  decreases
however if surgery is offered when the patient has a good pre-operative ejection fraction, left
ventricular function may improve to normal.
Key References: 
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Study design 
Case-control study
The study shall be a retrospective study for a defined term at the tertiary institution, Inkosi
Albert Luthuli Central Hospital.
The study will seek to compare all patients with rheumatic mitral regurgitation in terms of
their  baseline cardiac  function  and post-operative  outcome.  There shall  be 4 arms to the
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study: those patients with ejection fraction less than 40%, 40-49%, 50-59% and greater than
60%, the latter being the control group. The study groups shall be compared with each other
and then with the control group. The results shall then be statistically evaluated to determine
whether the study groups with impaired left ventricular function have a successful outcome
after surgery.
Study population 
The study population shall be accessed via a tertiary state institution, Inkosi Albert Luthuli
Central  Hospital  via their  computerised database.  A list  of patients that  underwent mitral
valve replacement for rheumatic mitral regurgitation between 2007-2011 shall be compiled.
Sampling strategy 
Stratified random sampling
Statistical planning (variables / confounders) 
The variables shall be the functional class (according to the New York Heart Association
classification),  ejection  fraction,  pulmonary  artery  systolic  pressures,  electrocardiographic
rhythm and clinical signs of heart failure.
Sample size 
It is envisaged that over a five-year period, we will harvest fifty patients with severe mitral
regurgitation and impaired  left  ventricular  function;  and twenty age- and gender-matched
controls.
Inclusion / exclusion criteria 
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Only patients with rheumatic mitral regurgitation shall be considered. The exclusion criteria
shall  include  concomitant  aortic  valve  disease,  ischaemic  mitral  regurgitation  and  mitral
stenosis as these are confounding pathologies. There shall be no restrictions in terms of age,
gender, race or social status.
Data collection methods and tools 
This shall be a retrospective study where a chart review shall be conducted for all patients
who meet criteria for the study, and their clinical and echocardiographic features recorded
pre- and post-operatively.  Microsoft Access shall be employed to collect the patient data.
Four sets of data shall be used for the four arms of the study. The variables that shall be
studied for each patient shall be identified and the information recorded for each patient. This
will enable ease of reference for statistical analysis for each variable.
Data analysis techniques 
Data shall be obtained from a tertiary cardiology centre and cardiothoracic surgery unit. A
statistician shall be consulted to analyse and determine the significance of the results. Bias
shall  be minimised as echocardiography is an objective cardiac investigation.  Only charts
with  adequately  documented  data  will  be included  in the  analysis.  Validity  in  this  study
depends  on  the  accuracy  of  measurement  of  left  ventricular  function.  In  this  study,  left




This shall be a quantitative study.  The paired t-Test shall be used to compare pre- and post-
operative  echocardiographic  data,  and to  compare  the  study groups to  the  control  group.
Confidence intervals, odds ratios and p-values shall be computed for the variables.
Study location 
Inkosi Albert Luthuli Central Hospital, Durban, South Africa
Study period 
2007-2011
Limitations to the study 
This study does not include patients with concomitant aortic valve disease, ischaemic mitral
regurgitation  or  mitral  stenosis  as  these  disease  processes  cause  different  pathological
responses in the myocardium and shall confound the clinical and echocardiographic outcome.
No further limitations could be identified at this point.
Ethical considerations
This  is  a  retrospective  chart  review  detailing  pre-  and  post-operative  findings  around  a
disease  process.  Patients  shall  be  identified  by  their  hospital  numbers  by  the  principal
investigator  and  the  supervisors  only.  Clinical  and  echocardiographic  outcomes  shall  be
evaluated; there shall be no intervention applied to the patients. Thus patients’ identities shall
be secured and there shall  be no harm inflicted nor benefit  derived for the patient  as an
individual.
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The National Institutes of Health (NIH) Office of Extramural Research certifies 
that Sharen Maharaj successfully completed the NIH Web-based training 
course “Protecting Human Research Participants”.
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Certification Number: 1256036 
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